Record MS-N197 · Supportive care · Last literature search and appraisal: 31 October 2026
Evidence at a glance
- Evidence label: Mixed sham-controlled evidence
- Potential benefit: Subjective hand/foot symptoms and the EORTC CIPN questionnaire improved, but the objective Total Neuropathy Score did not differ significantly.
- Risk: Ear pressure is usually low risk but can cause local pain, skin irritation or infection; it should not delay dose assessment or neurologic evaluation.
- What this evidence is about: Management of established chemotherapy-induced peripheral neuropathy during taxane treatment; no cancer-control outcome.
What was studied
Fifty-one people with breast cancer receiving taxane treatment were randomized 1:1 in a double-blind sham-controlled trial. A nurse applied different ear points weekly for three weeks. Generalized estimating equations favored active treatment for hand and foot numerical ratings and the EORTC QLQ-CIPN20 (all reported P<0.05). The Total Neuropathy Score moved in the same direction but was not significantly different. One participant withdrew with nausea and mild fever; causality was not established in the abstract.
What the evidence cannot establish
Small sample, short intervention, several outcomes and no absolute effects or confidence intervals in the abstract. The mismatch between subjective and objective findings is important. Appraisal was limited to the indexed abstract; full text was not verified. Funding, conflicts, clinically meaningful thresholds and detailed harms were not reported there.
Symptom improvement is not evidence of tumor shrinkage, delayed recurrence or longer survival. This record does not support replacing oncology treatment.
Practical safety context
Tell the oncology team promptly about progressive numbness, weakness, falls, severe pain or loss of function; chemotherapy dose/timing decisions are medical decisions. Do not place seeds or tape on broken, infected or allergic skin, and stop if the ear becomes painful or inflamed.
Questions for the care team
- Has neuropathy severity been documented with neurologic and functional assessment?
- Could another condition be contributing?
- What objective and patient-reported measures will determine whether this is helping?
Sources checked
Source note: Publication dates refer to the indexed paper; links were checked on 31 October 2026. A registry entry verifies design or status, not efficacy. Unreported fields are not assumed to be absent.
Education only: This evidence summary is not personal medical advice. Decisions about symptoms, treatment interactions and complementary care belong with your oncology team.
